Ascendis Pharma A/S
NASDAQ:ASNDBiotechnology
-$0.05 today
- Market cap
- $17.73B
- Beta
- 0.39
- P/E (TTM)
- 24.5
- EPS (TTM)
- $8.21
Volume 0.57M
Average 0.64M
ASND Operating Income
Profit from core operations after operating expenses, before interest and taxes.
Ascendis Pharma A/SNASDAQ: ASND
Operating Income · Q3 FY2026 · quarter ended Sep 2026
Operating income growth accelerates
Q3 FY2026 operating income of €123.84M rose 1026.1% year over year, ahead of the +252.5% change in trailing-twelve-month operating income. Sequentially, it rose 95.2% from the prior quarter.
Context
- Operating income amounted to 18.9% of revenue in FY2025, down 57.7 pp from a year earlier.
- Operating income grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether operating income reaches the consensus estimate from 13 analysts of €1.23B (+1036.5%) for the fiscal year ending Dec 2026, a step up from the +53.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- €123.84M+95.2% QoQ
- Last fiscal yearDec 2025
- -€130.89M+53.0% YoY
- LTMSep 2026
- €222.29M+252.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +1026.1% | -3482.9% | -4509.0 pp |
| 1 year | +53.0% | +1036.5% | +983.5 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Income history
EUR · from the income statement
- Latest · FY2025
- (130.89M) EUR
- Year-over-year change
- +53.0%
| Period | Period end | Operating Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (130.89M) | +53.0% |
| FY2024 | 2024-12-31 | (278.76M) | +38.8% |
| FY2023 | 2023-12-31 | (455.54M) | +18.9% |
| FY2022 | 2022-12-31 | (561.81M) | -24.4% |
| FY2021 | 2021-12-31 | (451.79M) | — |
Operating Income vs competitors
How ASND compares with its peers on the latest reported figures
- Peers report in different currencies, so operating income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +252.5% is the 2nd highest of 11, against a peer median of -6.2%.
- Operating income amounts to 18.4% of revenue for ASND, versus a peer median of 44.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.4B USD | -3.1% | +15.7% | 44.5% | |
| LTM Sep 2026 | $881.2M USD | +60.2% | +35.5% | 23.8% | |
| LTM Sep 2026 | €222.29M EUR | +252.5% | — | 18.4% | |
| LTM Mar 2026 | $35.9M USD | +259.6% | — | 11.4% | |
| LTM Jun 2026 | $6.41M USD | -93.7% | -26.5% | 0.8% | |
SEPNSepterna, Inc. | LTM Sep 2026 | -$73.39M USD | +4.7% | — | 76.2% |
MBXMBX Biosciences, Inc. Common Stock | LTM Sep 2026 | -$160.33M USD | -76.4% | — | — |
| LTM Mar 2026 | -$185.25M USD | -584.4% | — | 577.5% | |
| LTM Mar 2026 | -$561.78M USD | -9.4% | — | 83.9% | |
| LTM Jun 2026 | -$817.54M USD | +18.6% | — | 71.9% | |
| LTM Sep 2026 | -$81.76B USD | -13383.8% | +49.1% | 8.0% | |
| Peer median (excluding ASND) | — | -6.2% | +25.6% | 44.5% | |
Competitors are the stored peer set for ASND. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 7.78M | 51.17M | 266.72M | 363.64M | 691.71M |
| Cost of Revenue | 3.52M | 12.14M | 44.4M | 44.26M | 103.18M |
| Gross Profit | 4.26M | 39.04M | 222.32M | 319.38M | 588.53M |
| Gross Margin | 54.7% | 76.3% | 83.4% | 87.8% | 85.1% |
| Research & Development | 295.87M | 379.62M | 413.45M | 307M | 283.5M |
| Selling, General & Admin | 160.18M | 215.85M | 258.79M | 284.55M | 435.92M |
| Operating Expenses | 456.05M | 600.85M | 677.86M | 598.15M | 719.42M |
| Depreciation & Amortization | 15.39M | 17.96M | 18.91M | 17.71M | 17M |
| EBITDA | (364.64M) | (529.18M) | (411.17M) | (290.02M) | (109.8M) |
| EBITDA Margin | -4688.1% | -1034.1% | -154.2% | -79.8% | -15.9% |
| Operating Income | (451.79M) | (561.81M) | (455.54M) | (278.76M) | (130.89M) |
| Operating Margin | -5808.6% | -1097.9% | -170.8% | -76.7% | -18.9% |
| Interest Income | 692K | 7.43M | 16.86M | 14.36M | 14.7M |
| Interest Expense | 3.91M | 30.68M | 44.07M | 65.5M | 77.46M |
| Other Income / Expenses | 67.85M | (16M) | (18.6M) | (94.48M) | (73.37M) |
| Income Before Tax | (383.94M) | (577.82M) | (474.14M) | (373.24M) | (204.26M) |
| Pre-Tax Margin | -4936.3% | -1129.1% | -177.8% | -102.6% | -29.5% |
| Income Tax Expense | (367K) | 5.38M | 7.3M | 4.84M | 14.78M |
| Net Income | (383.58M) | (583.19M) | (481.45M) | (378.08M) | (219.03M) |
| Net Margin | -4931.6% | -1139.6% | -180.5% | -104.0% | -31.7% |
| EPS (Basic) | (7.00) | (10.40) | (8.55) | (6.53) | (3.62) |
| EPS (Diluted) | (7.00) | (10.40) | (8.55) | (6.53) | (3.62) |
| Weighted Avg Shares | 54.77M | 56.07M | 56.29M | 57.89M | 60.61M |
| Weighted Avg Shares (Diluted) | 54.77M | 56.07M | 56.29M | 57.89M | 60.61M |
Ascendis Pharma A/S
NASDAQ:ASND
Intrinsic Alpha fair value
Locked
Current Price
$270.33
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.